What technology area does this patent fall under?

Primary CPC classification A61K31/47. Mapped technology areas include Human Necessities.

When was this patent published?

Publication date Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Methods of treatment for cystic fibrosis

Patent metadata
Field	Value
Publication number	US-12186306-B2
Application number	US-202117546649-A
Country	US
Kind code	B2
Filing date	Dec 9, 2021
Priority date	Dec 10, 2020
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof.The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of treating cystic fibrosis comprising daily administration of: (a) 250 mg of Compound I: or an equivalent amount of a pharmaceutically acceptable salt thereof; and (b) 21.24 mg Compound II calcium salt hydrate Form D: and (c) 100 mg of Compound III: or an equivalent amount of a pharmaceutically acceptable salt thereof. 2. A method of treating cystic fibrosis comprising daily administration of: (a) 250 mg of Compound I: (b) 21.240 mg of Compound II calcium salt hydrate Form D: and (c) 100 mg of Compound III: (Compound III), to a patient in need thereof. 3. The method of claim 1 or claim 2 , wherein Compounds I, II, and III are administered in separate compositions. 4. The method of claim 1 or claim 2 , wherein Compounds I, II, and III are administered in a single composition. 5. The method of claim 1 or claim 2 , wherein Compounds I, II, and III are administered as two compositions once daily, each composition comprising 125 mg of Compound I, 10.62 mg of Compound II calcium salt hydrate Form D, and 50 mg of Compound III. 6. The method of claim 1 , wherein the patient is homozygous for the F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation or has an F508del/minimal function CFTR genotype, a F508del/gating CFTR genotype, or a F508del/residual function CFTR genotype. 7. The method of claim 1 , wherein the patient has a heterozygous CFTR genotype and has one F508del CFTR mutation. 8. The method of claim 7 , wherein the patient has one CFTR mutation selected from: 711 + 3A > G L206W K1060T 2789 + 5G > A R347H A1067T 3272 − 26A > G R352Q G1069R 3849 + 10 kb C > T A455E R1070Q E56K S549N R1070W P67L S549R F1074L R74W G551D D1152H D110E G551S G1244E D110H D579G S1251N R117C E831X S1255P R117H S945L D1270N G178R S977F G1349D E193K F1052V. 9. The method of claim 7 , wherein the patient has one CFTR mutation selected from: 3141del9 E822K G1244E 546insCTA F191V G1249R A46D F311del G1349D A120T F311L H139R A234D F508C H199Y A349V F508C; S1251N H939R A455E F575Y H1054D A554E F1016S H1085P A1006E F1052V H1085R A1067T F1074L H1375P D110E F1099L I148T D110H G27R I175V D192G G85E I336K D443Y G126D I502T D443Y; G576A; R668C G178E I601F D579G G178R I618T D614G G194R I807M D836Y G194V I980K D924N G314E I1027T D979V G463V I1139V D1152H G480C I1269N D1270N G551D I1366N E56K G551S K1060T E60K G576A L15P E92K G576A; R668C L165S E116K G622D L206W

Assignees

Vertex Pharma

Inventors

Classifications

A61K31/47Primary
Quinolines; Isoquinolines · CPC title
A61K31/4045
Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin · CPC title
A61K9/2054
Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title
A61K2300/00
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
A61P11/00
Drugs for disorders of the respiratory system · CPC title

Patent family

Related publications grouped by family.

View patent family 79287581

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12186306B2 cover?: This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof.The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
Who is the assignee on this patent?: Vertex Pharma
What technology area does this patent fall under?: Primary CPC classification A61K31/47. Mapped technology areas include Human Necessities.
When was this patent published?: Publication date Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).